Enovis (NYSE:ENOV) Updates FY 2025 Earnings Guidance

Enovis (NYSE:ENOV) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 3.100-3.250 for the period, compared to the consensus estimate of 3.160. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a “buy” rating and set a $65.00 target price on shares of Enovis in a research note on Thursday, November 7th.

Enovis Stock Down 3.6 %

ENOV stock traded down $1.53 during trading hours on Wednesday, reaching $40.58. 1,063,454 shares of the stock were exchanged, compared to its average volume of 959,522. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -18.53 and a beta of 1.94. The firm’s 50-day moving average is $44.96 and its 200-day moving average is $44.37. Enovis has a 12 month low of $38.27 and a 12 month high of $63.96. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. On average, equities research analysts expect that Enovis will post 2.79 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.